BDBM416983 (+-)-1-(3-(aminomethyl)phenyl)-N-(5-(3-cyclopropyl-1-isobutyramido-1-(pyridin-3-yl)propyl)-2-fluorophenyl)-3-(trifluoromethyl)-1H-pyrazole-5-carboxamide::US10329260, Compound 244j::US10633345, Compound 244j::US10689346, Compound 244j::US11203574, Compound 244j::US11685721, Compound 244j::US11708332, Compound 244j

SMILES CC(C)C(=O)NC(CCC1CC1)(c1cccnc1)c1ccc(F)c(NC(=O)c2cc(nn2-c2cccc(CN)c2)C(F)(F)F)c1

InChI Key InChIKey=POAUUALSNYEBRU-UHFFFAOYSA-N

Data  7 KI

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 7 hits for monomerid = 416983   

TargetPlasma kallikrein(Homo sapiens (Human))
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM416983((+-)-1-(3-(aminomethyl)phenyl)-N-(5-(3-cyclopropyl...)
Affinity DataKi:  25.1nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM416983((+-)-1-(3-(aminomethyl)phenyl)-N-(5-(3-cyclopropyl...)
Affinity DataKi:  25.1nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM416983((+-)-1-(3-(aminomethyl)phenyl)-N-(5-(3-cyclopropyl...)
Affinity DataKi:  25.1nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates. In these experiments, 2...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM416983((+-)-1-(3-(aminomethyl)phenyl)-N-(5-(3-cyclopropyl...)
Affinity DataKi:  25.1nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM416983((+-)-1-(3-(aminomethyl)phenyl)-N-(5-(3-cyclopropyl...)
Affinity DataKi:  25.1nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM416983((+-)-1-(3-(aminomethyl)phenyl)-N-(5-(3-cyclopropyl...)
Affinity DataKi:  25.1nMAssay Description:Plasma kallikrein activity assay. The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic s...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM416983((+-)-1-(3-(aminomethyl)phenyl)-N-(5-(3-cyclopropyl...)
Affinity DataKi:  25.1nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent